紫杉醇联合卡铂同步放化疗在食管癌患者中的应用效果

Application effects of Paclitaxel combined with Carboplatin concurrent chemoradiotherapy in patients with esophageal cancer

目的:观察紫杉醇联合卡铂同步放化疗在食管癌患者中的应用效果。方法:选取2015年9月至2017年1月该院收治的84例食管癌患者进行前瞻性研究,按照随机数字表法分为观察组与对照组各42例。两组均行同步放化疗,放疗方案相同,对照组采用卡铂注射液化疗,观察组在对照组基础上联合紫杉醇注射液化疗,比较两组疗效、生存率、复发率、转移率和不良反应发生率。结果:观察组治疗总有效率为71.43%,明显高于对照组的35.71%,差异有统计学意义(P<0.05);观察组1年生存率为95.24%,高于对照组的73.81%,差异有统计学意义(P<0.05);观察组2年生存率为92.86%,高于对照组的66.67%,差异有统计学意义(P<0.05);观察组4年生存率为73.81%,高于对照组的45.24%,差异有统计学意义(P<0.05);观察组4年复发率为14.29%,低于对照组的42.86%,差异有统计学意义(P<0.05);观察组4年转移率为9.52%,低于对照组的38.10%,差异有统计学意义(P<0.05);治疗期间,两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:紫杉醇联合卡铂同步放化疗在食管癌患者中的应用效果优于单纯卡铂同步放化疗,可提高疗效和患者生存率,降低复发率和转移率。

Objective: To observe application effects of Paclitaxel combined with Carboplatin concurrent chemoradiotherapy in patients with esophageal cancer. Methods: A prospective study was conducted on 84 patients with esophageal cancer admitted to this hospital from September 2015 to January 2017. They were divided into observation group and control group according to the random number table method, 42 cases in each. Both groups were treated with concurrent chemoradiotherapy, and the radiotherapy regimen was the same. The control group was treated with Carboplatin injection, while the observation group was combined with Paclitaxel injection chemotherapy on the basis of that of the control group.The efficacy, the survival rate, the recurrence rate, the metastasis rate, and the incidence of adverse reactions were compared between the two groups.Results: The total effective rate of the observation group was 71.43%, which was significantly higher than 35.71% of the control group, and the difference was statistically significant(P<0.05). The 1-year survival rate of the observation group was 95.24%, which was higher than 73.81% of the control group, and the difference was statistically significant(P<0.05). The 2-year survival rate of the observation group was 92.86%, which was higher than 66.67% of the control group, and the difference was statistically significant(P<0.05). The 4-year survival rate of the observation group was 73.81%, which was higher than 45.24% of the control group, and the difference was statistically significant(P<0.05). The 4-year recurrence rate of the observation group was 14.29%, which was lower than 42.86% of the control group, and the difference was statistically significant(P<0.05).The 4-year metastasis rate of the observation group was 9.52%, which was lower than 38.10% of the control group, and the difference was statistically significant(P<0.05). However, during the treatment, there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusions: Paclitaxel combined with Carboplatin concurrent chemoradiotherapy in the patients with esophageal cancer is superior to single carboplatin concurrent chemoradiotherapy alone, which can improve the efficacy and the survival rate, and reduce the recurrence rate and the metastasis rate.